Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

Article

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.

Date/Time: Tuesday, May 26, 2020 at 8 PM EST

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Click here to register today!

Topics:

  • Review of data on adverse events and strategies for management
  • The CAR T cell experience and vein-to-vein time
  • Real-world experience using bridging therapy in the setting of new drug approvals and pending approvals

Faculty:

Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center

Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine

Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center

Sponsored By:

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.